Market
Scenario
The Global Stroke Disorder
And Treatment Market is presumed to demonstrate a healthy CAGR during the
forecast period (2016-2022) owing to the rising high blood pressure patients,
asserts Market Research Future (MRFR). Stroke is
referred to as the condition which occurs when clot is formed in the artery and oxygen supply is cut off. Brain cells thus
get deprived of oxygen and start to die. Heart and brain strokes can strike any
moment and can be fatal. Stroke is considered as
one of the leading causes of death across the world with higher
prevalence in the geriatric population.
Drivers
and Constraints Impacting the Market
With increasing
consumption of alcohol and diabetic patients, the global stroke disorder and
treatment market is likely to flourish. Also, the increasing prevalence of
cardiovascular diseases is highly influencing the market across the globe. Brain
problems and heart problems are considered
as the most dangerous medical issues across the world with expensive medication
and treatments. Thus, the market offering treatment for it is lucrative. The
market is further accelerated by the huge
patient pool along with rising geriatric population across the globe. Moreover,
atrial fibrillation, hypertension, and coronary heart diseases are contributing
to the growth of the market.
On the
flip side, high cost of treatment adversely affects the growth of
the market. Moreover, the lack of
transparent reimbursement scenario is also likely to dampen the stroke disorder
and treatment market during the assessment period.
Global
Stroke Disorder and Treatment Market: Segmental Analysis
The global stroke disorder
and treatment market has been segmented on the basis of type, medicine, treatment, and
region.
By mode of type, the
global stroke disorder and treatment market has been
segmented into ischemic stroke and
hemorrhagic strokes. Among these, the weakened blood vessel leakage is referred to as hemorrhagic stroke. Ischemic stroke
generally occurs due to an obstruction within a blood vessel which
supplies blood to the brain.
By mode of medicine, the
global stroke disorder and treatment market has been
segmented into anticoagulants/antiplatelet, anti-hypertensive.
By mode of treatment, the
global stroke disorder and treatment market has been
segmented into tissue plasminogen activator (TPA), carotid
endarterectomy, surgical treatment, endovascular procedures, and others. TPA is
referred to as an enzyme involved in the breakdown of blood clots and dissolves
them. It is a less invasive procedure and is
used for treating problems affecting the blood vessels like aneurysm.
Competitive
Dashboard
The prominent players operating
the global stroke disorder and treatment market are AstraZeneca (U.K), Bayer
Pharma AG (Germany), Novartis AG (Switzerland), Daiichi Sankyo (Japan), and
Pfizer (U.S).
Regional
Insights
Geographically, the stroke
disorder and treatment market span across regions namely, Europe, North
America, Asia Pacific, and Rest-of-the-World.
Among these, the North
America region is presumed to dominate the stroke diagnostics and therapeutics market and is likely to maintain its dominance.
The growth is attributed to the rising awareness
among the population regarding the symptoms of stroke
followed by the several harmful effects associated with high glucose level in
blood. With technological advancements and high-end research, and rising public
interest, the demand for stroke disorder and treatment is likely to trigger in
the coming years. Moreover, encouraging healthcare infrastructure and higher
healthcare expenditure are some of the major factors contributing to the growth
of the stroke disorder and treatment market.
European
holds the second-largest position with high diabetic population. Moreover, the growing percentage of
diabetes mellitus population is directly proportionate to the associated risk
of stroke in individuals, thereby contributing to the market growth during the
assessment period. Additionally, technological advancements and healthcare
research are further influencing the
market growth.
Industry
Updates
CERENOVUS business has
recently launched the single largest global registry, the EXCELLENT Registry, in order to collect and analyze stroke-inducing blood clots removed from the brain with its
EMBOTRAP II Revascularization Device. The EXCELLENT Registry is likely to enroll up to 1000 ischemic stroke patients in
as many as 50 clinical sites in Europe and the United States.
Browse Complete 85 Pages Premium Research Report Enabled with Respective
Tables and Figures @ https://www.marketresearchfuture.com/reports/stroke-disorder-treatment-market-1651
Detailed
Table of Contents:
1. Report Prologue
2. Introduction
2.1 Definition
2.2 Scope Of The Study
2.2.1 Research Objective
2.2.2 Assumptions
2.2.3 Limitations
2.3 Market Structure
2.4. Market Segmentation
3. Research Methodology
3.1 Research Process
3.2 Primary Research
3.3 Secondary Research
3.4 Market Size
Estimation
3.5 Forecast Model
4. Market Dynamics
4.1 Drivers
4.2 Restraints
4.3 Opportunities
4.4 Mega Trends
4.5 Macroeconomic
Indicators
5. Market Factor Analysis
5.1 Value Chain Analysis
5.2 Porters Five Forces
Analysis
5.3 Demand & Supply:
Gap Analysis
5.4 Pricing Analysis
5.5 Investment
Opportunity Analysis
5.6 Merger And
Acquisition Landscape
...Continued!
About US:
Market
Research Future (MRFR), enable customers to unravel the complexity of various
industries through Cooked Research Report (CRR), Half-Cooked Research Reports
(HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market
Research & Consulting Services.
Contact Us:
Market
Research Future
Office
No. 528, Amanora Chambers
Magarpatta
Road, Hadapsar,
Pune
- 411028
Maharashtra,
India
Phone:
+1 646 845 9312
Email:
sales@marketresearchfuture.com
No comments:
Post a Comment